Nephron Research upgraded Inspire Medical (INSP) to Buy from Hold.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical upgraded to Buy from Hold at Stifel
- Positive Outlook for Inspire Medical Systems: Increased Reimbursement Rates and Strategic Advantages Drive Buy Rating
- Inspire Medical sees $90M-$100M income tax benefit for FY25
- Inspire Medical Systems to Release Tax Valuation Allowance
- Inspire Medical Faces Legal Heat Over Product Launch